



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Lorenz et al.) Group Art Unit: 1644
Serial No.: 09/816,697) Examiner: Phillip Gambel
Filed: March 23, 2001)
For: A NOVEL P-SELECTIN)
GLYCOPROTEIN LIGAND)
(PSGL-1) BINDING PROTEIN)
AND USES THEREFOR)

#16/B
Goiga
4/11/03

RECEIVED

APR 10 2003

TECH CENTER 1600/2900

BOX AMENDMENT
Commissioner for Patents and Trademarks
Washington, DC 20231

AMENDMENT AND RESPONSE

In reply to the Office Action dated November 15, 2002, the period for reply having been extended for two months by a request for extension and fee payment filed concurrently herewith, please amend the application as follows:

IN THE SPECIFICATION:

Replace the five paragraphs beginning on page 3, at line 19, and ending on page 4, at line 23, with the following five paragraphs:

-- In one embodiment, a SLIC-1 nucleic acid molecule of the invention is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to the nucleotide sequence (e.g., to the entire length of the nucleotide sequence) shown in SEQ ID NO:1, or a complement thereof. In a preferred embodiment, the isolated nucleic acid molecule includes the nucleotide sequence shown in SEQ ID NO:1, or a complement thereof. In another preferred embodiment, the

B
FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

BEST AVAILABLE COPY